Switching to lower Zepbound dose better for maintaining weight loss than stopping therapy

Adults with obesity receiving tirzepatide 10 mg or 15 mg may be able to maintain most of their weight loss after switching to a lower dose of the drug, according to findings from the phase 3 SURMOUNT-MAINTAIN trial. Results from a phase 3b trial presented at the European Congress on Obesity and simultaneously published in The Lancet showed that adults who lost 5% or more body weight at 60 weeks